Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7976931 | 0.81 | PDE4A (0.60) | PDE4AKCNH2 | |
| SCHEMBL7994385 | 0.78 | PDE4A (0.53) | PDE4AKCNH2 | |
| SCHEMBL21215123 | 0.75 | PDE4A (0.71) | PDE4AKCNH2 | |
| SCHEMBL7977187 | 0.68 | PDE4A (0.61) | PDE4AKCNH2 | |
| SCHEMBL14045227 | 0.67 | PDE4A (0.78) | PDE4AKCNH2 | |
| SCHEMBL7988711 | 0.65 | PDE4A (0.67) | PDE4AKCNH2 | |
| SCHEMBL7987426 | 0.65 | PDE4A (0.65) | PDE4AKCNH2 | |
| SCHEMBL7906817 | 0.65 | PDE4A (0.84) | PDE4AKCNH2 | |
| SCHEMBL7383186 | 0.64 | PDE4A (0.53) | PDE4AKCNH2 | |
| SCHEMBL7383450 | 0.64 | PDE4A (0.75) | PDE4AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | PDE4A 559/4885KCNH2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.